Determinants of plasma factor VIIa levels in humans

S. Eichinger, P. M. Mannucci, F. Tradati, A. A. Arbini, R. D. Rosenberg, K. A. Bauer

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Several enzymes can activate factor VII in vitro, but the protease responsible for generating factor VIIa in vivo has not been determined. Using recombinant tissue factor that has undergone a COOH-terminal truncation, a sensitive functional assay has been established for measuring plasma factor VIIa levels. To evaluate the mechanism responsible for the generation of factor VIIa in vivo, we measured the levels of this enzyme after administering purified concentrates of factor IX and factor VIII to patients with severe deficiencies of these clotting factors. In patients with hemophilia B, factor VIIa levels were initially reduced to 0.5 ± 0.1 ng/mL and gradually increased to normal after infusing 100 U/kg of body weight (BW) of factor IX. Despite these increases, there were no significant changes in the generation of factor Xa or thrombin. In patients with hemophilia A, only a slight reduction in factor VIIa levels (2.5 ± 1.3 ng/mL) was observed as compared with controls (3.3 ± 1.1 ng/mL) and no significant changes were observed after factor VIII levels were normalized. The administration of recombinant factor VIIa (10 μg/kg BW) to patients with factor VII deficiency increased the mean circulating level of the enzyme to 118 ng/mL, but this only resulted in normalization of the levels of the activation peptides of factor IX and factor X. The above data indicate that factor IXa is primarily responsible for the basal levels of free factor VIIa generated in vivo (ie, in the absence of thrombosis or provocative stimuli) and that changes in the plasma concentrations of free factor VIIa in the blood do not necessarily lead to alterations in the extent of factor X activation.

Original languageEnglish
Pages (from-to)3021-3025
Number of pages5
JournalBlood
Volume86
Issue number8
Publication statusPublished - 1995

Fingerprint

Factor VIIa
Plasmas
Factor X
Factor VII
Factor IX
Factor VIII
Enzymes
Factor VII Deficiency
Factor IXa
Chemical activation
Body Weight
Hemophilia B
Factor Xa
Blood Coagulation Factors
Hemophilia A
Thromboplastin
Thrombin
Assays
Thrombosis
Blood

ASJC Scopus subject areas

  • Hematology

Cite this

Eichinger, S., Mannucci, P. M., Tradati, F., Arbini, A. A., Rosenberg, R. D., & Bauer, K. A. (1995). Determinants of plasma factor VIIa levels in humans. Blood, 86(8), 3021-3025.

Determinants of plasma factor VIIa levels in humans. / Eichinger, S.; Mannucci, P. M.; Tradati, F.; Arbini, A. A.; Rosenberg, R. D.; Bauer, K. A.

In: Blood, Vol. 86, No. 8, 1995, p. 3021-3025.

Research output: Contribution to journalArticle

Eichinger, S, Mannucci, PM, Tradati, F, Arbini, AA, Rosenberg, RD & Bauer, KA 1995, 'Determinants of plasma factor VIIa levels in humans', Blood, vol. 86, no. 8, pp. 3021-3025.
Eichinger S, Mannucci PM, Tradati F, Arbini AA, Rosenberg RD, Bauer KA. Determinants of plasma factor VIIa levels in humans. Blood. 1995;86(8):3021-3025.
Eichinger, S. ; Mannucci, P. M. ; Tradati, F. ; Arbini, A. A. ; Rosenberg, R. D. ; Bauer, K. A. / Determinants of plasma factor VIIa levels in humans. In: Blood. 1995 ; Vol. 86, No. 8. pp. 3021-3025.
@article{0aa7387cfb574d89b59f6456c530eaf5,
title = "Determinants of plasma factor VIIa levels in humans",
abstract = "Several enzymes can activate factor VII in vitro, but the protease responsible for generating factor VIIa in vivo has not been determined. Using recombinant tissue factor that has undergone a COOH-terminal truncation, a sensitive functional assay has been established for measuring plasma factor VIIa levels. To evaluate the mechanism responsible for the generation of factor VIIa in vivo, we measured the levels of this enzyme after administering purified concentrates of factor IX and factor VIII to patients with severe deficiencies of these clotting factors. In patients with hemophilia B, factor VIIa levels were initially reduced to 0.5 ± 0.1 ng/mL and gradually increased to normal after infusing 100 U/kg of body weight (BW) of factor IX. Despite these increases, there were no significant changes in the generation of factor Xa or thrombin. In patients with hemophilia A, only a slight reduction in factor VIIa levels (2.5 ± 1.3 ng/mL) was observed as compared with controls (3.3 ± 1.1 ng/mL) and no significant changes were observed after factor VIII levels were normalized. The administration of recombinant factor VIIa (10 μg/kg BW) to patients with factor VII deficiency increased the mean circulating level of the enzyme to 118 ng/mL, but this only resulted in normalization of the levels of the activation peptides of factor IX and factor X. The above data indicate that factor IXa is primarily responsible for the basal levels of free factor VIIa generated in vivo (ie, in the absence of thrombosis or provocative stimuli) and that changes in the plasma concentrations of free factor VIIa in the blood do not necessarily lead to alterations in the extent of factor X activation.",
author = "S. Eichinger and Mannucci, {P. M.} and F. Tradati and Arbini, {A. A.} and Rosenberg, {R. D.} and Bauer, {K. A.}",
year = "1995",
language = "English",
volume = "86",
pages = "3021--3025",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Determinants of plasma factor VIIa levels in humans

AU - Eichinger, S.

AU - Mannucci, P. M.

AU - Tradati, F.

AU - Arbini, A. A.

AU - Rosenberg, R. D.

AU - Bauer, K. A.

PY - 1995

Y1 - 1995

N2 - Several enzymes can activate factor VII in vitro, but the protease responsible for generating factor VIIa in vivo has not been determined. Using recombinant tissue factor that has undergone a COOH-terminal truncation, a sensitive functional assay has been established for measuring plasma factor VIIa levels. To evaluate the mechanism responsible for the generation of factor VIIa in vivo, we measured the levels of this enzyme after administering purified concentrates of factor IX and factor VIII to patients with severe deficiencies of these clotting factors. In patients with hemophilia B, factor VIIa levels were initially reduced to 0.5 ± 0.1 ng/mL and gradually increased to normal after infusing 100 U/kg of body weight (BW) of factor IX. Despite these increases, there were no significant changes in the generation of factor Xa or thrombin. In patients with hemophilia A, only a slight reduction in factor VIIa levels (2.5 ± 1.3 ng/mL) was observed as compared with controls (3.3 ± 1.1 ng/mL) and no significant changes were observed after factor VIII levels were normalized. The administration of recombinant factor VIIa (10 μg/kg BW) to patients with factor VII deficiency increased the mean circulating level of the enzyme to 118 ng/mL, but this only resulted in normalization of the levels of the activation peptides of factor IX and factor X. The above data indicate that factor IXa is primarily responsible for the basal levels of free factor VIIa generated in vivo (ie, in the absence of thrombosis or provocative stimuli) and that changes in the plasma concentrations of free factor VIIa in the blood do not necessarily lead to alterations in the extent of factor X activation.

AB - Several enzymes can activate factor VII in vitro, but the protease responsible for generating factor VIIa in vivo has not been determined. Using recombinant tissue factor that has undergone a COOH-terminal truncation, a sensitive functional assay has been established for measuring plasma factor VIIa levels. To evaluate the mechanism responsible for the generation of factor VIIa in vivo, we measured the levels of this enzyme after administering purified concentrates of factor IX and factor VIII to patients with severe deficiencies of these clotting factors. In patients with hemophilia B, factor VIIa levels were initially reduced to 0.5 ± 0.1 ng/mL and gradually increased to normal after infusing 100 U/kg of body weight (BW) of factor IX. Despite these increases, there were no significant changes in the generation of factor Xa or thrombin. In patients with hemophilia A, only a slight reduction in factor VIIa levels (2.5 ± 1.3 ng/mL) was observed as compared with controls (3.3 ± 1.1 ng/mL) and no significant changes were observed after factor VIII levels were normalized. The administration of recombinant factor VIIa (10 μg/kg BW) to patients with factor VII deficiency increased the mean circulating level of the enzyme to 118 ng/mL, but this only resulted in normalization of the levels of the activation peptides of factor IX and factor X. The above data indicate that factor IXa is primarily responsible for the basal levels of free factor VIIa generated in vivo (ie, in the absence of thrombosis or provocative stimuli) and that changes in the plasma concentrations of free factor VIIa in the blood do not necessarily lead to alterations in the extent of factor X activation.

UR - http://www.scopus.com/inward/record.url?scp=0028818742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028818742&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 3021

EP - 3025

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -